Abstract
HLA system plays a key role in the tumor cells’ escape from immune surveillance. Herein is the first report on the correlation of the susceptibility to breast cancer with HLA class II markers in Tunisia. Molecular ty** of HLA-DRB1 and -DQB1 loci was undertaken for 70 Tunisian female patients. Comparison of allele and haplotype distribution between patients and 70 female control subjects reveals a negative association between HLA-DRB1*07-DQB1*02 and the incidence of breast cancer in the Tunisian population. (Pathology Oncology Research Vol 12, No 2, 79–81)
Similar content being viewed by others
References
Abrahamova J, Majsky A: HLA system and some neoplastic diseases. Acta Univ Carol Med Monogr 123: 1–80, 1988
Apple RJ, Erlich HA, Klitz W, et al: HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 6:157–162, 1994
Bidwell JL, Soong TW, Raymond PA, et al: HLA genoty** of colorectal carcinoma in the Chinese population. Hum Immunol 34:19–23, 1992
Biswal BM, Kumar R, Julka PK, et al: Human leucocytic antigens (HLA) in breast cancer. Int J Med Sci 52:177–183, 1998
Bodmer WF: The HLA system: structure and function. J Clin Pathol 40:948–958, 1987
Bouillence C, Deneufbourg JM: Positive correlation between breast cancer incidence and HLA antigens. Oncology 36:156–159, 1979
Buyse I, Dacorte R, Baens M, et al: Rapid DNA ty** of class II antigens using the polymerase chain reaction and reverse dot blot hybridization. Tissue Antigens 41:1–14, 1993
Casoli C, Zanelli P, Adorni A, et al: Serological and molecular study on the HLA phenotype of female breast cancer patients. Eur J Cancer 30: 1207–1208, 1994
Campbell RD, Trowsdale J: Map of the human MHC. Immunol Today 14 349, 1993
Chaudhuri S, Cariappa A, Tang M, et al: Genetic susceptibility to breast cancer, HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci USA 97: 11451–11454, 2000
De Jong MM, Nolte IM, De Vries EGE, et al: The HLA class III subregion is responsible for an increased breast cancer risk. Hum Mol Genet 12:2311–2319, 2003
Feinmesser M, Sulkes A, Morgenstern S, et al: HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol 53: 286–291, 2000
Ferguson TA, Green DR, Griffith TS: Cell death and immune privilege. Int Rev Immunol 21:153–172, 2002
Ghaderi A, Talei A, Gharesi-Fard B, et al: HLA-DRB1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res 7: 39–41, 2001
Hammond MG, Appadoo B, Brain P: HLA and cancer in South African Indians. Tissue Antigens 14:296–302, 1979
Hmida S, Gauthier A, Dridi A, et al: HLA class II polymorphism in Tunisians. Tissue Antigens 45: 63–68, 1995
Igney FH, Krammer PH: Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2:277–288, 2002
Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning. A Laboratory Manual. Cold Spring Laboratory Press, Cold Spring Harbor NY, 1982
Mestiri S, Bouaouina N, Ahmed SB, et al: Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp 70–2: susceptibility and prognostic implications in breast carcinoma. Cancer 91: 672–678, 2001
Park KS, Mok JW, Ko HE, et al: Polymorphisms of tumor necrosis factors A and B in breast cancer. Eur J Immunogenet 29: 7–10, 2002
Pellegris G, Illeni MT, Vaglini M, et al: HLA antigens in malignant melanoma patients. Tumori 66: 51–58, 1980
Ragoussis J, Monaco A, Mockridge I, et al: Cloning of the HLA class II region in yeast artificial chromosomes. Proc Natl Acad Sci USA 88: 3753–3757, 1991
Sastre-Garau X, Loste MN, Vincent-Salomon A, et al: Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer 69: 159–164, 1996
Subira ML, Crisci CD, Zornoza G, et al: Breast cancer and histocompatibility antigens. Allegrol Immunopathol (Madr) 7: 411–416, 1979
Wu MS, Hsieh RP, Huang SP, et al: Association of HLA-DQB1*0301 and HLA-DQB1*0602 with different subtypes of gastric cancer in Taiwan. Jpn J Cancer Res 93:404–410, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harrath, A.B., Loueslati, B.Y., Troudi, W. et al. HLA class II polymorphism: Protective or risk factors to breast cancer in Tunisia?. Pathol. Oncol. Res. 12, 79–81 (2006). https://doi.org/10.1007/BF02893448
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893448